These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 30515857)

  • 1. A clinical trial on the acute effects of methadone and buprenorphine on actual driving and cognitive function of healthy volunteers.
    Strand MC; Vindenes V; Gjerde H; Mørland JG; Ramaekers JG
    Br J Clin Pharmacol; 2019 Feb; 85(2):442-453. PubMed ID: 30515857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of Single Doses of Methadone and Buprenorphine in Blood and Oral Fluid in Healthy Volunteers and Correlation With Effects on Psychomotor and Cognitive Functions.
    Strand MC; Ramaekers JG; Gjerde H; Mørland J; Vindenes V
    J Clin Psychopharmacol; 2019; 39(5):489-493. PubMed ID: 31305338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Less impairment on one portion of a driving-relevant psychomotor battery in buprenorphine-maintained than in methadone-maintained patients: results of a randomized clinical trial.
    Soyka M; Hock B; Kagerer S; Lehnert R; Limmer C; Kuefner H
    J Clin Psychopharmacol; 2005 Oct; 25(5):490-3. PubMed ID: 16160628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Less driving impairment on buprenorphine than methadone in drug-dependent patients?
    Soyka M; Horak M; Dittert S; Kagerer S
    J Neuropsychiatry Clin Neurosci; 2001; 13(4):527-8. PubMed ID: 11748323
    [No Abstract]   [Full Text] [Related]  

  • 5. MDMA and alcohol effects, combined and alone, on objective and subjective measures of actual driving performance and psychomotor function.
    Kuypers KP; Samyn N; Ramaekers JG
    Psychopharmacology (Berl); 2006 Sep; 187(4):467-75. PubMed ID: 16830130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparing the effects of oxazepam and diazepam in actual highway driving and neurocognitive test performance: a validation study.
    Jongen S; Vuurman EFPM; Ramaekers JG; Vermeeren A
    Psychopharmacology (Berl); 2018 Apr; 235(4):1283-1294. PubMed ID: 29500585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can patients receiving opioid maintenance therapy safely drive? A systematic review of epidemiological and experimental studies on driving ability with a focus on concomitant methadone or buprenorphine administration.
    Strand MC; Fjeld B; Arnestad M; Mørland J
    Traffic Inj Prev; 2013; 14(1):26-38. PubMed ID: 23259516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cognitive functioning in opioid-dependent patients treated with buprenorphine, methadone, and other psychoactive medications: stability and correlates.
    Rapeli P; Fabritius C; Kalska H; Alho H
    BMC Clin Pharmacol; 2011 Aug; 11():13. PubMed ID: 21854644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic and pharmacodynamic properties of buprenorphine after a single intravenous administration in healthy volunteers: a randomized, double-blind, placebo-controlled, crossover study.
    Escher M; Daali Y; Chabert J; Hopfgartner G; Dayer P; Desmeules J
    Clin Ther; 2007 Aug; 29(8):1620-31. PubMed ID: 17919544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A single-center, randomized, double-blind, placebo-controlled, crossover investigation of the effects of fexofenadine hydrochloride 180 mg alone and with alcohol, with hydroxyzine hydrochloride 50 mg as a positive internal control, on aspects of cognitive and psychomotor function related to driving a car.
    Ridout F; Shamsi Z; Meadows R; Johnson S; Hindmarch I
    Clin Ther; 2003 May; 25(5):1518-38. PubMed ID: 12867226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of intranasal esketamine (84 mg) and oral mirtazapine (30 mg) on on-road driving performance: a double-blind, placebo-controlled study.
    van de Loo AJAE; Bervoets AC; Mooren L; Bouwmeester NH; Garssen J; Zuiker R; van Amerongen G; van Gerven J; Singh J; der Ark PV; Fedgchin M; Morrison R; Wajs E; Verster JC
    Psychopharmacology (Berl); 2017 Nov; 234(21):3175-3183. PubMed ID: 28755104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of long-term maintenance treatment with buprenorphine on complex psychomotor and cognitive function.
    Shmygalev S; Damm M; Weckbecker K; Berghaus G; Petzke F; Sabatowski R
    Drug Alcohol Depend; 2011 Sep; 117(2-3):190-7. PubMed ID: 21353749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuropsychological functioning of opiate-dependent patients: a nonrandomized comparison of patients preferring either buprenorphine or methadone maintenance treatment.
    Loeber S; Kniest A; Diehl A; Mann K; Croissant B
    Am J Drug Alcohol Abuse; 2008; 34(5):584-93. PubMed ID: 18720267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Cannabidiol and Δ9-Tetrahydrocannabinol on Driving Performance: A Randomized Clinical Trial.
    Arkell TR; Vinckenbosch F; Kevin RC; Theunissen EL; McGregor IS; Ramaekers JG
    JAMA; 2020 Dec; 324(21):2177-2186. PubMed ID: 33258890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opioids and traffic safety--focus on buprenorphine.
    Soyka M
    Pharmacopsychiatry; 2014 Jan; 47(1):7-17. PubMed ID: 24222013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing cognitive and psychomotor performance under long-term treatment with transdermal buprenorphine in chronic noncancer pain patients.
    Dagtekin O; Gerbershagen HJ; Wagner W; Petzke F; Radbruch L; Sabatowski R
    Anesth Analg; 2007 Nov; 105(5):1442-8, table of contents. PubMed ID: 17959980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antidepressants and driver impairment: empirical evidence from a standard on-the-road test.
    Ramaekers JG
    J Clin Psychiatry; 2003 Jan; 64(1):20-9. PubMed ID: 12590619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Next-day effects of ramelteon (8 mg), zopiclone (7.5 mg), and placebo on highway driving performance, memory functioning, psychomotor performance, and mood in healthy adult subjects.
    Mets MA; de Vries JM; de Senerpont Domis LM; Volkerts ER; Olivier B; Verster JC
    Sleep; 2011 Oct; 34(10):1327-34. PubMed ID: 21966064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of acute treatment with ramelteon, triazolam, and placebo on driving performance, cognitive function, and equilibrium function in healthy volunteers.
    Miyata A; Iwamoto K; Kawano N; Kohmura K; Yamamoto M; Aleksic B; Ebe K; Noda A; Noda Y; Iritani S; Ozaki N
    Psychopharmacology (Berl); 2015 Jun; 232(12):2127-37. PubMed ID: 25533998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.